-
Company Profile
![]()
Sandoz Inc – Company Profile
Sandoz Inc (Sandoz), a division of Novartis AG, is a generic pharmaceutical company which develops, manufactures and distributes and sells a range of prescription medicines and protein and biosimilars worldwide. The company also provides intermediary products including active pharmaceutical ingredients (APIs), and biotechnology manufacturing services to other companies. It provides active ingredients and finished dosage forms of pharmaceuticals in the areas of dermatology, cancer, cardiovascular, respiratory, metabolism, central nervous system, pain, ophthalmic, gastrointestinal, and hormonal therapies. Sandoz distributes products to...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EV-PURE in Pulmonary Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EV-PURE in Pulmonary Fibrosis Drug Details: EV-PURE is under development for the treatment of chronic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SCO-240 in Diabetes
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SCO-240 in DiabetesDrug Details:SCO-240 is under development for the treatment of diabetes, cholelithiasis, gall stone, primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anti-ILT4 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anti-ILT4 in Solid Tumor Drug Details: The drug candidate is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986408 in Neuroblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986408 in Neuroblastoma Drug Details: BMS-986408 is under development for the treatment of advanced, unresectable/metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Chemotherapy Effects
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Denosumab Biosimilar in Chemotherapy EffectsDrug Details:denosumab biosimilar (GP-2411) is under development for the treatment of postmenopausal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Glucocorticoid-Induced Osteoporosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Denosumab Biosimilar in Glucocorticoid-Induced OsteoporosisDrug Details:denosumab biosimilar (GP-2411) is under development for the treatment of postmenopausal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Humoral Hypercalcemia of Malignancy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Denosumab Biosimilar in Humoral Hypercalcemia of MalignancyDrug Details:denosumab biosimilar (GP-2411) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Osteopetrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Denosumab Biosimilar in OsteopetrosisDrug Details:denosumab biosimilar (GP-2411) is under development for the treatment of postmenopausal osteoporosis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-9606a in Fallopian Tube Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DS-9606a in Fallopian Tube Cancer Drug Details:DS-9606a is under development for the treatment of solid tumors....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Golcadomide in Refractory Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Golcadomide in Refractory Chronic Lymphocytic Leukemia (CLL)Drug Details:CC-99282 is under development for the treatment of relapsed...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis (Sandoz International GmbH)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug Details: denosumab biosimilar (GP-2411) is under development...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M&A in the Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry...
-
Company Profile
![]()
Novartis AG – Company Profile
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company...
Add to Basket -
Product Insights
Novartis AG Pipeline Insight and Competitive Landscape, 2023
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company...
-
Sector Analysis
![]()
New Drug Approvals and Their Contract Manufacture – 2023 Edition
Explore actionable market insights from the following data in our ‘New Drug Approvals and Their Contract Manufacture’ report. This report is required reading for - CMO executives who must have a deep understanding of drug approvals and outsourcing to make strategic planning and investment decisions. Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. Private equity investors who need a deeper understanding of the market to...
-
Thematic Analysis
![]()
State of the Biopharmaceutical Industry 2023
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you - Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months. Understand the most impactful emerging technologies - Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview...
-
Product Insights
![]()
Net Present Value Model: Oxycontin
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Oxycontin Drug Details Oxycodone hydrochloride (OxyContin,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – denosumab biosimilar
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry denosumab biosimilar Drug Details Denosumab biosimilar is under development for the treatment of post...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – denosumab biosimilar
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry denosumab biosimilar Drug Details Denosumab biosimilar (SB16) is under development for treatment of osteoporosis....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.